TruScreen Group (TRU) H1 2026 earnings summary

Executive summary

• Product sales for the first half of FY2026 reached NZ$860k, with full-year revenue guidance maintained at NZ$2.8m.

• China remains the strongest market, while new public screening programs in Zimbabwe and Vietnam are set to begin in 2H FY2026.

• Strategic alliances, including with DaltonBio, and new distributors in India and South Africa expand market reach and HPV product range.

• A successful capital raise of NZ$4m is expected to support the company to monthly cash flow positivity by late FY2026.

• Operating loss increased to NZ$1.36m due to deferred revenue and capital raise costs.

Financial highlights

• Revenue from product sales decreased 17% year-over-year to NZ$860,795 due to deferred programs.

• Net loss for the period was NZ$1,358,451, up from NZ$1,133,478 in the prior year.

• Net operating cash outflow rose to NZ$1.7m from NZ$0.9m year-over-year.

• Cash and cash equivalents at period end were NZ$2.2m.

• Gross margin on product sales remained stable, with cost of goods sold at NZ$639,230.

Outlook and guidance

• FY2026 revenue guidance affirmed at NZ$2.8m, with 2H expected to recover deferred revenue and reflect new program revenues.

• Public screening programs in Vietnam, Zimbabwe, and Uzbekistan are expected to contribute significantly in 2H FY2026, with public programs projected to contribute 20% of annual revenue.

• Company projects transition to monthly positive cash flow by late FY2026.